The effect of oral L-arginine supplementation on fasting glucose, HbA1c, nitric oxide and total antioxidant status in diabetic patients with atherosclerotic peripheral arterial disease of lower extremities

European Review for Medical and Pharmacological Sciences

Volumn 16, Issue 3, 2012, Pages 342-350

  Jablecka A ^a   Bogdanski P ^a   Balcer, N ^a   Cieslewicz A ^a   Skoluda A ^a   Musialik, K ^a  

^a POZNAN UNIVERSITY OF MEDICAL SCIENCES   (Poland)

Author keywords

Atherosclerosis; Diabetes mellitus; L arginine; Nitric oxide; Oxidative stress

Indexed keywords

ARGININE; GLUCOSE; HEMOGLOBIN A1C; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; NITRIC OXIDE; TRIACYLGLYCEROL;

ADULT; ANTIOXIDANT ACTIVITY; BODY MASS; CHOLESTEROL BLOOD LEVEL; CLINICAL ARTICLE; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIABETIC PATIENT; DIASTOLIC BLOOD PRESSURE; DIET SUPPLEMENTATION; DIET THERAPY; DISEASE ASSOCIATION; FEMALE; GLUCOSE BLOOD LEVEL; HUMAN; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; NUTRITIONAL ASSESSMENT; PERIPHERAL OCCLUSIVE ARTERY DISEASE; REVIEW; SYSTOLIC BLOOD PRESSURE; THERAPY EFFECT; TREATMENT DURATION; TREATMENT OUTCOME; TRIACYLGLYCEROL BLOOD LEVEL;

ANTIOXIDANTS; ARGININE; ATHEROSCLEROSIS; BLOOD GLUCOSE; DIABETES MELLITUS, TYPE 2; DIETARY SUPPLEMENTS; FASTING; FEMALE; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; LOWER EXTREMITY; MALE; MIDDLE AGED; NITRIC OXIDE; PERIPHERAL ARTERIAL DISEASE; REGIONAL BLOOD FLOW;

EID: 84859925204     PISSN: 11283602     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (51)

1. HALLER H. Endothelial function. General considerations. Drugs 1997;53:1-10. (Pubitemid 27101586)
2. SCHMID MI, DUNCAN BB, SHARRETT AR. Markers of inflammation and prediction of diabetes mellitus in adults (Atherosclerosis Risk in Communities Study), a cohort study. Lancet 1999;353:1649-1652. (Pubitemid 29224520)
3. TABIT CE, CHUNG WB, HAMBURG NM, VITA JA. Endothelial dysfunction in diabetes mellitus: molecular mechanisms and clinical implications. Rev Endocr Metab Disord 2010;11:61-74.
4. MCLELLAN K, PETROFSKY JS, ZIMMERMAN G, PROWSE M, BAINS G, LEE S. Multiple stressors and the response of vascular endothelial cells: the effect of aging and diabetes. Diabetes Technol Ther 2009;11:73-79.
5. NACCI C, TARQUINIO M, MONTAGNANI M. Molecular and clinical aspects of endothelial dysfunction in diabetes. Intern Emerg Med 2009;4:107-116.
6. KESSLER L, WIESEL ML, ATTALI P, MOSSARD JM, CAZENAVE J P, PINGET M. Von Willebrand factor in diabetic angiopathy. Diab Metab 1998;24:327-336. (Pubitemid 28453158)
7. COSSON E, PHAM I, VALENSI P, PARIÈS J, ATTALI JR, NITENBERG A. Impaired coronary endothelium-dependent vasodilation is associated with microalbuminuria in patients with type 2 diabetes and angiographically normal coronary arteries. Diabetes Care 2006;29:107-112. (Pubitemid 44033440)
8. FUJITA H. Vascular endothelial cell dysfunction in diabetes mellitus. Nippon Rinsho 1999;57:573-577.
9. WU J, LEI MX, LIU L, HUANG YJ. Changes of endothelium-dependent vasodilation in patients with impaired glucose tolerance and type 2 diabetes. Zhong Nan Da Xue Xue Bao Yi Xue Ban 2007;32:609-614.
10. KAYE JM, STANTON KG, MCCAAN VJ, VASIKARAN SD, BURKE V, TAYLOR RR, VAN BOCKXMEER FM. Homocysteine, folate, methylene tetrahydrofolate reductase genotype and vascular morbidity in diabetic subjects. Clin Sci (Lond) 2002;102:631-637. (Pubitemid 34620893)
11. LITTLE PJ, TOPLISS DJ, MUDALIAR S, LAW RE. Perioxisome Proliferator-Activated Receptors and Diabetic Vasculature. In: Diabetes and Cardiovascular Disease. Ed. Marzo SP, Stern DM, Lippincott, Williams & Wilkins, Philadelphia, Baltimore etc. 2004:75-91.
12. PIWOWAR A, KNAPIK-KORDECKA M, WARWAS M. Stres oksydacyjny a dysfunkcja s ród blonka w cukrzycy typu 2. Pol Merk Lek 2008; XXV: 120-123.
13. ROBERTS W, RIBA R, HOMER-VANNIASINKAM S, FARNDALE RW, NASEEM KM. Nitric oxide specifically inhibits integrin-mediated platelet adhesion and spreading on collagen. J Thromb Haemost 2008;6:2175-2185.
14. GIARDINO I, EDELSTEIN D, BROWNLEE M. Blc-2 expression or antioxidants prevent hyperglycemia-induced formation of intracellular advanced glycation end products in bovine endothelial cells. J Clin Invest 1996;97:1422-1428. (Pubitemid 26097031)
15. JUDE EB, ELEFTHERIADOU I, TENTOLOURIS N. Peripheral arterial disease in diabetes - a review. Diabet Med 2010;27:4-14.
16. MICKER M, CHCISKI P, SYNOWIEC T. Postȩpowanie w przewleklym niedokrwieniu konczyn dolnych. Przew Lek 2006;5:12-21.
17. DE HARO MIRALLES J, MARTÍNEZ-AGUILAR E, FLOREZ A, VARELA C, BLEDA S, ACIN F. Nitric oxide: link between endothelial dysfunction and inflammation in patients with peripheral arterial disease of the lower limbs. Interact Cardiovasc Thorac Surg 2009;9:107-112.
18. GRYGLEWSKI RJ. Nitric oxide in atherosclerosis. Thromb Haemorrh Disorders 1990;2:1-9.
19. RANG HP DALE MM, RITTER JM. Biosynthesis of nitric oxide and its control. In Pharmacology (Third Ed.), Churchill Livingstone 2000:203-213.
20. HOWELL K, COSTELLO CM, SANDS M, DOOLEY I, MCLOUGHLIN P. L-Arginine promotes angiogenesis in the chronically hypoxic lung: a novel mechanism ameliorating pulmonary hypertension. Am J Physiol Lung Cell Mol Physiol 2009;296:1042-1050.
21. EL-MISSIRY MA, OTHMAN AI, AMER MA. L-Arginine ameliorates oxidative stress in alloxan-induced experimental diabetes mellitus. J Appl Toxicol 2004;24:93-97. (Pubitemid 38477569)
22. KOCHAR NI, UMATHE SN. Beneficial effects of L-arginine against diabetes-induced oxidative stress in gastrointestinal tissues in rats. Pharmacol Rep 2009;61:665-672.
23. MARTINA V, MASHA A, GIGLIARDI VR, BROCATO L, MANZATO E, BERCHIO A, MASSARENTI P. SETTANNI F, DELLA CASA L, BERGAMINI S, IANNONE A. Long-term N-acetylcysteine and L-arginine administration reduces endothelial activation and systolic blood pressure in hypertensive patients with type 2 diabetes. Diabetes Care 2008;31:940-944.
24. BLOOMGARDEN ZT. Cardiovascular disease in diabetes. Diabetes Care 2010;33:49-54.
25. KANNEL WB, MCGEE DL. Diabetes and cardiovascular disease. The Framingham study. JAMA 1979;241:2035-2038. (Pubitemid 9228506)
26. LAAKSO M. Cardiovascular disease in type 2 diabetes from population to man to mechanisms: the Kelly West Award Lecture 2008. Diabetes Care 2010;33:442-449.
27. PALUMBO PJ, MELTON LJ. Peripheral vascular disease and diabetes. In: Diabetes in America. 2nd edition. Ed. National Diabetes Group, National Institute of Diabetes and Kidney Diseases, Bethsheda 1995: pp. 401-408.
28. The Diabetes Control and Complications Trials Research Group. The effect of intensive treatment of diabetes on development of complications of diabetes mellitus. N Engl J Med 1993;32:977-986
29. KREINES K, JOHNSON E, ALBRINK M, KNATTERUD GL, LEVIN ME, LEWITAN A, NEWBERRY W, ROSE FA. The course of peripheral vascular disease in non-insulin-dependent diabetes. Diabetes Care 1985;8:235-243. (Pubitemid 15071438)
30. NISKANEN L, SIITONEN O, SUHONEN M, UUSITUPA MI. Medial artery calcification predicts cardiovascular mortality in patients with NIDDM. Diabetes Care 1994;17:1252-1256. (Pubitemid 24324967)
31. JACKOBY RM, NESTO RW. Acute myocardial infarction in the diabetic patients, pathophysiology, clinical course, and prognosis. J Am Coll Cardiol 1992;20:736-744.
32. LESLIE RD, COHEN RM. Biologic variability in plasma glucose, hemoglobin A1c, and advanced glycation end products associated with diabetes complications. J Diabetes Sci Technol 2009;1:635-643.
33. HANEFELD M, FISHER S, JULIUS U, SCHULZE J, SCHWANEBECK U, SCHMECHEL H, ZIEGELASCH HJ, LINDNER J. Risk factors for myocardial infarction and death in newly detected NIDDM, the Diabetes Intervention Study, 11-year follow-up. Diabetologia 1996;39:1577-1583. (Pubitemid 26397370)
34. Decode Study Group European Diabetes Epidemiology Group. Glucose tolerance and mortality, comparison of WHO and American Diabetes Association criteria. Lancet 1999;354:617-621.
35. KHAW WT, WAREHMAN N, LUBEN R. Glycated hemoglobin, diabetes and mortality in men in Norfolk cohort of European Prospective Investigation of Cancer and Nutrition (EPIC Norfolk). Br Med J 2001;322:15-28.
36. JABLECKA A, CHCISKI P, KRAUSS H, MICKER M, AST J. The influence of two different doses of L-arginine oral supplementation on nitric oxide (NO) concentration and total antioxidant status (TAS) in atherosclerotic patients. Med Sci Monit 2004;10:29-32.
37. PIATTI PM, MONTI LD, VALSECCHI G, MAGNI F, SETOLA E, MARCHESI F, GALLI-KIENLE M. POZZA G, ALBERTI KG. Long-term oral L-arginine administration improves peripheral and hepatic insulin sensitivity in type 2 diabetic patients. Diabetes Care 2001;24:875-880. (Pubitemid 33636062)
38. GHISELLI A, SERAFINI M, NATELLA F, SCACCINI C. Total antioxidant capacity as a tool to assess redox status, critical view and experimental data. Free Radic Biol Med 2000;29:1106-1114.
39. RAMANA KV, CHANDRA D, SRIVASTAVA S, BHATNAGAR A, SRIVASTAVA SK. Nitric oxide regulates the polyol pathway of glucose metabolism in vascular smooth muscle cells. FASEB-J 2003;17:417-425. (Pubitemid 36292957)
40. BÖGER RH, BODE-BÖGER SM, PHIVTHONG-NGAM L, BRANDES RP, SCHWEDHELM E, MÜGGE A, BÖHME M. TSIKAS D, FRÖLICH JC. Dietary L-arginine and alphatocopherol reduce vascular oxidative stress and preserve endothelial function in hypercholesterolemic rabbits via different mechanisms. Atherosclerosis 1998;141:31-43. (Pubitemid 28539414)
41. CHECINSKI P. Badania nad skutecznoscia̧ suplementacji L-argininy u chorych z miazdzycowym niedokrwieniem konczyn dolnych. Ordynator Leków 2002;3:7-9.
42. CASSONE-FALDETTA M, LAURENTI O, DESIDERI G., BRAVI MC, DE LUCA O, MARINUCCI MC, DE MATTIA G, FERRI C. L-arginine infusion decreases plasma total homocysteine concentrations through increased nitric oxide production and decreased oxidative status in Type II diabetic patients. Diabetologia 2002;45:1120-1127. (Pubitemid 34985288)
43. LAM MA, PATTISON DI, BOTTLE SE, KEDDIE DJ, DAVIES MJ. Nitric oxide and nitroxides can act as efficient scavengers of protein-derived free radicals. Chem Res Toxicol 2008;21:2111-2119.
44. RAJAPAKSE NW, MATTSON DL. Role of L-arginine in nitric oxide production in health and hypertension. Clin Exp Pharmacol Physiol 2009;36:249-255.
45. TENENBAUM A, FISMAN EZ, MOTRO M. L-Arginine, rediscovery in progress. Cardiology 1998;90:153-159.
46. SLAWISKI M, GRODZISKA L, KOSTKA-TRBKA E, BIERON K, GOSZCZ A, GRYGLEWSKI RJ. L-arginine-substrate for no synthesis-its beneficial effects in therapy of patients with peripheral arterial disease, comparison with placebo-preliminary results. Acta Physiol Hung 1996;84:457-458. (Pubitemid 126476460)
47. WIERUSZ-WYSOCKA B, ZOZULINSKA D, KEMPA M, SKOWROSKI M, MURAWSKA A. Evaluation of nitric oxide metabolites concentration in patients with type I diabetes. Pol Arch Med Wew 1998;100:139-144. (Pubitemid 128521445)
48. SORBIEVA L, MANN GE. Dysfunction of endothelial nitric oxide signaling pathway in diabetes and hyperglycemia. Exp Physiol 1997;82:43-53.
49. KOHLI R, MEININGER CJ, HAYNES TE, YAN W, SELF JT, WU G. Dietary L-arginine supplementation enhances endothelial nitric oxide synthesis in streptozocin-induced diabetic rats. J Nutr 2004;134:600-608. (Pubitemid 38298503)
50. PETRIE JR, UEDA S, WEBB DJ, ELLIOTT HL, CONNELL JM. Endothelial nitric oxide production and insulin sensitivity. A physiological link with implications for pathogenesis of cardiovascular disease. Circulation 1996;93:1331-1333. (Pubitemid 26099342)
51. BALON TW, NADLER JL. Nitric oxide release is present from incubated skeletal muscle preparations. J Appl Physiol 1997;82:2519-2521.